Europe Breast Cancer Screening Market Analysis
The Europe Breast Cancer Screening Market is experiencing rapid growth, projected to reach US$ 2.21 billion by 2032, up from US$ 1.03 billion in 2023, with a robust CAGR of 8.85% from 2024 to 2032. This growth is being driven by a combination of factors, including increasing breast cancer cases, technological advancements in screening methods, heightened awareness, and the supportive role of government policies.
Request a free sample copy of the report: https://www.renub.com/europe-breast-cancer-screening-market-mammography-mri-and-ultrasound-forecast-to-2022-1097-p.php
Breast Cancer Screening Market Overview
Breast cancer remains one of the most prevalent cancers, especially among women. With more than 2 million new cases reported globally in 2019, breast cancer is the second most common cancer worldwide. In Europe, it is the most common cancer among women, with an estimated 565,500 cases in 2019 alone. This growing incidence of breast cancer is a major driver for the European breast cancer screening market.
As of recent statistics, the UK alone sees over 58,000 breast cancer diagnoses each year, with similar rates in other European countries such as Spain, Scotland, and Wales. Early detection through screening methods like mammograms is vital to improving survival rates, making the demand for screening technologies and services a top priority across the continent.
Key Drivers Fueling Market Growth
- Increasing Prevalence of Breast Cancer
The rising incidence of breast cancer is one of the primary factors fueling the growth of the screening market in Europe. Factors such as unhealthy lifestyles, poor dietary habits, and increased alcohol consumption contribute to this rise. Additionally, longer life expectancies and genetic predispositions are leading to higher rates of breast cancer diagnoses, which in turn is increasing the demand for screening services.
According to EUROPA DONNA, the European Coalition Against Breast Cancer, 1 in 8 women in Europe will be diagnosed with breast cancer before the age of 85. This high rate of incidence ensures the continuous need for regular screening services, creating an expanding market for breast cancer diagnostic tools and treatments.
- Government Support and Awareness Campaigns
Government initiatives to improve breast cancer awareness and provide access to screening services are crucial to the market’s growth. In Europe, national health services and nonprofit organizations often conduct free screening programs, helping to increase the number of people getting screened and fostering early detection. The NHS in the UK, for instance, has allocated millions in funding to expand breast cancer screening centers.
In addition, public awareness campaigns such as the “Breast Cancer Affects Us All” initiative in Germany aim to increase understanding and encourage more women to get screened. These campaigns not only help reduce the stigma around breast cancer but also educate women about the importance of early detection.
- Technological Advancements in Screening Methods
Advancements in screening technologies are another key driver of the market. Innovations in mammography, such as digital mammography and 3D mammography, have improved the accuracy and efficiency of early detection. Additionally, technologies like MRI and ultrasound are being used alongside traditional mammograms to offer more comprehensive screening options, especially for women with dense breast tissue. The development of AI-powered diagnostic tools is also enhancing the ability to identify potential breast cancer earlier, making these technologies vital in screening programs.
- Increased Focus on Clinical Trials and Research
Ongoing clinical trials and research are helping to further refine breast cancer screening methods. For example, a clinical trial in the Netherlands, supported by the University Medical Center in Utrecht, aims to compare the effectiveness of mammography plus MRI against mammography alone for women with dense breasts. The growing number of these clinical studies is expected to produce groundbreaking data that will enhance screening accuracy and efficacy, ultimately benefiting the market.
Germany’s Role in the European Breast Cancer Screening Market
Germany holds a significant share of the European breast cancer screening market, driven by a high incidence of breast cancer and increasing public awareness. Startups like Vara, based in Berlin, have made strides in improving access to breast cancer screening. By raising funds to hire experienced breast radiologists and introducing new, data-driven methods for screening, Vara is helping to make early detection more accessible.
Furthermore, German companies such as FUJIFILM Europe GmbH are also contributing to the market’s growth by launching advanced screening equipment. The company’s Harmony edition of the Amulet Innovality mammography system represents a leap forward in digital mammography technology, offering greater accuracy and efficiency in detecting breast cancer.
Key Companies Leading the Market
The Europe Breast Cancer Screening Market features several prominent players, including:
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
These companies are at the forefront of research and development, bringing forth new drugs and diagnostic tools that are improving outcomes for breast cancer patients.
Key Market Developments
Several recent initiatives are shaping the market:
- January 2023: The UK government allocated USD 12.2 million (GBP 10 million) to build 29 new breast cancer screening centers to accelerate the identification and treatment of breast cancer. This initiative will increase access to screening and improve early detection rates.
- September 2022: The European Union (EU) funded the CanScreen-ECIS project, which aims to enhance cancer screening across Europe by modernizing the European Cancer Information System (ECIS). This initiative will improve the efficiency and scope of breast cancer screening programs in the region.
Challenges and Opportunities
While the European breast cancer screening market is growing, there are challenges to address. Access to screening services in rural areas, screening disparities between different socioeconomic groups, and screening hesitancy among certain populations need to be tackled. However, with continued innovation in screening technologies, increased government funding, and the growing availability of comprehensive screening programs, these challenges present opportunities for companies to develop solutions that promote equity and wider access.
Related Report :
Europe In-Vitro Diagnostics Market
Global Clinical Chemistry Analyzer Market
Global Radiology Information System Market
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:rajat@renub.com
Leave a Reply